相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability
Hui Wang et al.
CANCER MEDICINE (2022)
An integrative pan cancer analysis of RET aberrations and their potential clinical implications
Lei Zhou et al.
SCIENTIFIC REPORTS (2022)
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2022)
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Diana Bradford et al.
CLINICAL CANCER RESEARCH (2021)
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
C. M. Della Corte et al.
ESMO OPEN (2021)
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions
Janice Kim et al.
CLINICAL CANCER RESEARCH (2021)
RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas
Angela Chou et al.
MODERN PATHOLOGY (2020)
REToma: a cancer subtype with a shared driver oncogene
Takashi Kohno et al.
CARCINOGENESIS (2020)
Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development
Anthony W-H Chan et al.
JOURNAL OF PATHOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
KIFSB-RET fusion gene and its correlation with clinicopathological and prognostic features in lung cancer: a meta-analysis
Xiao-Feng Cong et al.
ONCOTARGETS AND THERAPY (2019)
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
F. Pietrantonio et al.
ANNALS OF ONCOLOGY (2018)
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
Ari Vanderwalde et al.
CANCER MEDICINE (2018)
RET rearrangements are actionable alterations in breast cancer
Bhavna S. Paratala et al.
NATURE COMMUNICATIONS (2018)
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Evgeny Yakirevich et al.
CLINICAL CANCER RESEARCH (2016)
Acinar Cell Carcinoma of the Pancreas in the United States: Prognostic Factors and Comparison to Ductal Adenocarcinoma
C. Max Schmidt et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Large-scale analysis of the human and mouse transcriptomes
AI Su et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)